Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Source: Globenewswire
AlloNK® Presentation: Artiva Biotherapeutics will present new Phase 1/2 data on AlloNK® combined with rituximab for treating relapsed/refractory B-cell non-Hodgkin lymphoma at the ASGCT Annual Meeting, highlighting prolonged response duration and deep B-cell depletion.
Manufacturing Process: The company will also showcase the scalability and consistency of the AlloNK manufacturing process in a separate poster presentation during the event.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
